Innovotech

Innovotech Debt/EBITDA

The Total Debt to EBITDA Ratio of Innovotech (IOT.V) as of Oct 16, 2026 is 1.32. In the previous year, Total Debt to EBITDA Ratio was 0.20 — a change of 555.19% (higher).

Debt/EBITDA

1.32

YoY

555.19%

Last updated:

Total Debt to EBITDA Ratio of Innovotech is 2025 1.32 . Total Debt to EBITDA Ratio of Innovotech was 2024 0.20 . It decreases by 555.19% higher compared to the previous year.

The Innovotech Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2014
-0.80 CAD
Jan 1, 2015
-0.65 CAD
Jan 1, 2016
1.45 CAD
Jan 1, 2017
2.91 CAD
Jan 1, 2018
-0.79 CAD
Jan 1, 2019
-2.48 CAD
Jan 1, 2020
0.20 CAD
Jan 1, 2025
1.32 CAD
The Innovotech Debt/EBITDA history
YEARDebt/EBITDAYoY
1.32+555.19%
0.20-108.11%
-2.48+215.41%
-0.79-127.02%
2.91+100.70%
1.45-322.02%
-0.65-18.25%
-0.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innovotech Stock analysis

What does Innovotech do? Innovotech Inc is a company based in Edmonton, Alberta, Canada, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company went public on May 28, 2003, with its ticker symbol IOT.V and ISIN CA45772U1049. Innovotech Inc. focuses on proprietary assay kits used in microbial biofilm research, offering a range of services and products related to antimicrobial testing and biofilm analysis. The company provides contract research services including Antimicrobial Contract Research, testing for Minimum Inhibitory Concentration (MIC) and Minimum Biofilm Eradication Concentration (MBEC), and specialized testing for antimicrobial and anti-biofilm materials. Additionally, Innovotech offers services such as Bacteriophage Testing, Customized Antimicrobial Testing, and Analytical Capabilities. The company also markets MBEC Assay Kits, Order Biofilm Assays, and Coated MBEC Assay Lids. Innovotech Inc. is involved in biofilm research, including scientific publications and a SEM Library, and develops antimicrobial silver products like AgreGuard-1 Silver Antimicrobial for crop protection and InnovoSIL Antimicrobial Silver Products. The company's website is https://innovotech.ca/. Innovotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innovotech stock

Total Debt to EBITDA Ratio of Innovotech is 1.32 in 2025.

Total Debt to EBITDA Ratio of Innovotech changed from 0.20 to 1.32, representing a 555.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Innovotech since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Innovotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Innovotech

All Key Metrics — Innovotech